Formononetin (Synonyms: 刺芒柄花素; Biochanin B; Flavosil; Formononetol)

目录号: HY-N0183 纯度: 98.99%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

Formononetin 是一种有效的 FGFR2 抑制剂，IC₅₀ 为 ~4.31 μM。 Formononetin 有效抑制血管生成和肿瘤生长。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Formononetin Chemical Structure

CAS No. : 485-72-3

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥500	In-stock
5 mg	￥299	In-stock
10 mg	￥448	In-stock
50 mg	￥900	In-stock
100 mg	￥1200	In-stock
500 mg	￥2600	In-stock
1 g		询价
5 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Formononetin:

Formononetin-d₃-1 In-stock
Formononetin (Standard) 询价

MCE 顾客使用本产品发表的 14 篇科研文献

Formononetin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 FGFR 亚型特异性产品:

查看所有亚型

FGFR FGFR1 FGFR2 FGFR3 FGFR4 FGF21

生物活性
纯度 & 产品资料
参考文献

生物活性

Formononetin is a potent FGFR2 inhibitor with an IC₅₀ of ~4.31 μM. Formononetin potently inhibits angiogenesis and tumor growth^[1].

IC₅₀ & Target^[1]

FGFR2

4.31 μM (IC₅₀)

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A549	IC₅₀	> 100 μM Compound: 13	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 18440233]
A549	ED₅₀	2.87 μg/mL Compound: 11	Cytotoxicity against human A549 cells after 7 days Cytotoxicity against human A549 cells after 7 days	[PMID: 8201311]
B16-BL6	IC₅₀	> 100 μM Compound: 13	Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay	[PMID: 18440233]
BV-2	IC₅₀	> 100 μM Compound: 19	Anti-neuroinflammatory activity against mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay Anti-neuroinflammatory activity against mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay	[PMID: 25466192]
BV-2	IC₅₀	13.19 μM Compound: 2	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay	[PMID: 28911817]
DU-145	IC₅₀	> 100 μM Compound: Formononetin	Cytotoxicity against human DU145 cells after 72 hrs by MTT assay Cytotoxicity against human DU145 cells after 72 hrs by MTT assay	[PMID: 22633834]
ECa-109 cell line	IC₅₀	> 100 μM Compound: 1	Cytotoxicity against human EC109 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human EC109 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 28038329]
HCT-116	IC₅₀	60.97 μM Compound: Formononetin	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 22633834]
HeLa	IC₅₀	> 100 μM Compound: 13	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 18440233]
HeLa	IC₅₀	8.51 μM Compound: Formononetin	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 22633834]
HepG2	IC₅₀	60.5 μM Compound: 15	Anticancer activity against human HepG2 cells assessed as cell viability after 24 hrs by MTT assay Anticancer activity against human HepG2 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 24974349]
HT-1080	IC₅₀	> 100 μM Compound: 13	Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay	[PMID: 18440233]
HT-29	ED₅₀	6.43 μg/mL Compound: 11	Cytotoxicity against human HT-29 cells after 7 days Cytotoxicity against human HT-29 cells after 7 days	[PMID: 8201311]
Lewis lung carcinoma cell line	IC₅₀	> 100 μM Compound: 13	Cytotoxicity against mouse LLC cells after 72 hrs by MTT assay Cytotoxicity against mouse LLC cells after 72 hrs by MTT assay	[PMID: 18440233]
MCF7	ED₅₀	1.96 μg/mL Compound: 11	Cytotoxicity against human MCF7 cells after 7 days Cytotoxicity against human MCF7 cells after 7 days	[PMID: 8201311]
MDCK	CC₅₀	123 μM Compound: 3	Cytotoxicity against MDCK cells after 72 hrs Cytotoxicity against MDCK cells after 72 hrs	[PMID: 24313801]
MDCK	IC₅₀	38.2 μM Compound: 3	Antiviral activity against Influenza A virus J/8178/09 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs Antiviral activity against Influenza A virus J/8178/09 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs	[PMID: 24313801]
MDCK	IC₅₀	42.6 μM Compound: 3	Antiviral activity against Influenza A virus (A/Hong Kong/1/1968(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs Antiviral activity against Influenza A virus (A/Hong Kong/1/1968(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs	[PMID: 24313801]
MGC-803	IC₅₀	> 100 μM Compound: 1	Cytotoxicity against human MGC803 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human MGC803 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 28038329]
N9	IC₅₀	> 100 μM Compound: 4	Antineuroinflammatory activity in mouse N9 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay Antineuroinflammatory activity in mouse N9 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay	[PMID: 28073678]
PC-3	IC₅₀	57.01 μM Compound: 1	Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 28038329]
RAW264.7	IC₅₀	56.1 μM Compound: 6	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay	[PMID: 23743282]
SGC-7901	IC₅₀	2.17 μM Compound: Formononetin	Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay	[PMID: 22633834]
SH-SY5Y	IC₅₀	> 100 μM Compound: Formononetin	Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay	[PMID: 22633834]
U-937	IC₅₀	44 μM Compound: 6, formononetin	Antiproliferative activity against human U937 cells after 48 hrs by WST-8 assay Antiproliferative activity against human U937 cells after 48 hrs by WST-8 assay	[PMID: 17158054]
U-937	IC₅₀	45 μM Compound: 6, formononetin	Antiproliferative activity against human U937 cells after 72 hrs by WST-8 assay Antiproliferative activity against human U937 cells after 72 hrs by WST-8 assay	[PMID: 17158054]
U-937	IC₅₀	50 μM Compound: 6, formononetin	Antiproliferative activity against human U937 cells after 24 hrs by WST-8 assay Antiproliferative activity against human U937 cells after 24 hrs by WST-8 assay	[PMID: 17158054]

体外研究
(In Vitro)

Formononetin 是从 Astragalus membranaceus 中分离出来的主要异黄酮成分之一，已被证明具有多种药理益处。Formononetin 在人结肠癌细胞中具有抗血管生成活性。Formononetin 还通过下调人前列腺癌细胞中的 Akt/细胞周期蛋白 D1/CDK4 促进细胞周期停滞^[1]。
Formononetin (25-150 μM) 显著降低 FGF2 刺激的内皮细胞增殖^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	HUVECs
Concentration:	0, 10, 25, 50, 75, 100, and 150 μM
Incubation Time:
Result:	Significantly decreased the proliferation of HUVECs stimulated by FGF2 in a dose-dependent manner, while had little inhibitory effects on HUVECs that were not stimulated by FGF2.

体内研究
(In Vivo)

Formononetin 显著抑制肿瘤体积，并且与载体组相比，Formononetin 处理组的肿瘤重量得到显著抑制。Formononetin 处理耐受性良好，赋形剂组与 Formononetin 处理组体重无显著差异^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	BALB/c nude mice bearing MDA-MB-231 xenografts^[1]
Dosage:	100 mg/kg
Administration:	Treated daily by intragastric administration for 25 days
Result:	Inhibited breast cancer growth and angiogenesis in vivo.

分子量

268.26

Formula

C₁₆H₁₂O₄

CAS 号

485-72-3

性状

固体

颜色

White to off-white

中文名称

刺芒柄花素；生原禅宁 B；素普拉脑；芒柄花素

结构分类

初始来源

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

溶解性数据

细胞实验：

DMSO 中的溶解度 : ≥ 35 mg/mL (130.47 mM; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.7277 mL	18.6386 mL	37.2773 mL
5 mM	0.7455 mL	3.7277 mL	7.4555 mL
10 mM	0.3728 mL	1.8639 mL	3.7277 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 1 year; -20°C, 6 months。-80°C储存时，请在1年内使用， -20°C储存时，请在6个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (9.32 mM); 悬浊液; 超声助溶

此方案可获得 2.5 mg/mL的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (9.32 mM); 悬浊液; 超声助溶

此方案可获得 2.5 mg/mL的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案三

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (9.32 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

以下溶解方案，请直接配制工作液。建议现用现配，在短期内尽快用完。以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

方案一

请依序添加每种溶剂： 50% PEG300 50% Saline
Solubility: 5 mg/mL (18.64 mM); 悬浊液; 超声助溶
方案二

请依序添加每种溶剂： 0.5% CMC-Na/saline water
Solubility: 25 mg/mL (93.19 mM); 悬浊液; 超声助溶

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 98.99%

选择批次：

Data Sheet (639 KB) SDS (393 KB)

COA (284 KB) HNMR (248 KB) RP-HPLC (221 KB) LCMS (94 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Xiao Yu Wu,et al. Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models. Oncotarget. 2015 Dec 29;6(42):44563-78. [Content Brief]

Formononetin 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.7277 mL	18.6386 mL	37.2773 mL	93.1932 mL
	5 mM	0.7455 mL	3.7277 mL	7.4555 mL	18.6386 mL
	10 mM	0.3728 mL	1.8639 mL	3.7277 mL	9.3193 mL
	15 mM	0.2485 mL	1.2426 mL	2.4852 mL	6.2129 mL
	20 mM	0.1864 mL	0.9319 mL	1.8639 mL	4.6597 mL
	25 mM	0.1491 mL	0.7455 mL	1.4911 mL	3.7277 mL
	30 mM	0.1243 mL	0.6213 mL	1.2426 mL	3.1064 mL
	40 mM	0.0932 mL	0.4660 mL	0.9319 mL	2.3298 mL
	50 mM	0.0746 mL	0.3728 mL	0.7455 mL	1.8639 mL
	60 mM	0.0621 mL	0.3106 mL	0.6213 mL	1.5532 mL
	80 mM	0.0466 mL	0.2330 mL	0.4660 mL	1.1649 mL
	100 mM	0.0373 mL	0.1864 mL	0.3728 mL	0.9319 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

Formononetin (Synonyms: 刺芒柄花素; Biochanin B; Flavosil; Formononetol)

Customer Review

Other Forms of Formononetin:

MCE 顾客使用本产品发表的 14 篇科研文献

Formononetin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 FGFR 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Formononetin 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Formononetin (Synonyms: 刺芒柄花素; Biochanin B; Flavosil; Formononetol)

Customer Review

Other Forms of Formononetin:

Formononetin 相关抗体

MCE 顾客使用本产品发表的 14 篇科研文献

Formononetin 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 FGFR 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

Formononetin 相关抗体:

摩尔计算器

稀释计算器

Formononetin 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z